AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus
AbbVie shares climbed roughly 1% on Friday, closing in on the session peak at $222.73 after fluctuating between $219.54 and $222.77.
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call
Merck & Co shares climbed roughly 1.2% to $109.64 by Friday afternoon, finding footing after a volatile week for U.S. stocks. The health care sector showed strength, with the Health Care Select Sector SPDR ETF edging up about 0.6%, despite the broader market slide—the SPDR S&P 500 ETF dipped roughly 0.5%. Johnson & Johnson held steady, while Pfizer and Eli Lilly posted gains.
Johnson & Johnson stock today: JNJ steadies after talc court win, EU panel backs AKEEGA expansion
Johnson & Johnson shares held steady in midday trading Friday after a U.S. judge threw out a lawsuit alleging the company committed fraud to route talc claims through bankruptcy. The company also announced that a European drug panel supported a wider label for its AKEEGA prostate cancer treatment.
GSK share price dips in London as Exdensur rollout and Feb 4 results loom
GSK shares slipped 0.65% to 1,840 pence in early London trading on Friday. The stock kicked off at 1,836 pence, fluctuating between 1,823 and 1,843 pence.
Johnson & Johnson stock price: JNJ closes lower after talc fraud suit tossed — what investors watch next
Johnson & Johnson shares edged down 0.19% to close at $227.29 on Thursday. The drop came after a U.S. judge dismissed a fraud lawsuit targeting the company’s "Texas two-step" strategy, which involves moving talc liabilities into a subsidiary that then files for bankruptcy. U.S. District Judge Michael Shipp ruled the plaintiffs failed to prove they were harmed by the bankruptcy stays that paused cases from October 2021 through March 2025. J&J’s litigation head, Erik Haas, called the claims “wholly meritless.” During the session, the stock hit $230 and last changed hands at $227.98 in after-hours trading.
Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants
Eli Lilly shares ended little changed on Thursday after the drugmaker lined up another research collaboration, this time in autoimmune disease. The stock closed up 0.03% at $1,024.14, as Wall Street finished mixed.
Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next
Shares of Olema Pharmaceuticals Inc climbed 5.8% to $25.99 Thursday afternoon, boosting its market cap by roughly $127 million. Trading volume hit around 926,000 shares, with the stock swinging between $24.35 and $26.56.
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs
Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday, having peaked at $229.90 earlier. The stock had closed at $227.72 on Wednesday.
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near
Eli Lilly shares climbed Thursday after Repertoire Immune Medicines announced a partnership with the drugmaker worth up to $1.93 billion, including an $85 million upfront payment, plus milestone and royalty fees. Lilly was up 0.5% at $1,028.89 in late morning trading, while the S&P 500 slipped about 1.4%. Repertoire will lead early research using its Decode platform, which explores how T cells attack diseased cells, before Lilly takes the programs to the clinic and eventually the market.
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom
GSK shares edged up 0.34% to 1,823.75 pence early Thursday in London, recovering a bit after a 2.42% drop on Wednesday. Still, the stock is down 0.38% year to date.
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen
Johnson & Johnson shares rose 1.5% on Wednesday, ending the session at $227.72. The jump came after Morgan Stanley upgraded the healthcare giant, highlighting strong momentum from its newer drug portfolio.
Eli Lilly stock drops after hours: Medicare pricing talks and GLP-1 battle back in focus
Eli Lilly shares were down about 1.5% at $1,023.80 in after-hours trading on Wednesday, after swinging between $1,004.25 and $1,038.96 in the regular session.
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks
Johnson & Johnson shares climbed Wednesday following U.S. regulators’ green light for a new combination use of its blood-cancer drug, Darzalex Faspro, expanding the treatment’s approved indications.
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
Pfizer shares dropped 1.8% to $26.02 in early afternoon trading, having fluctuated between $25.97 and $26.39.
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Eli Lilly and Company shares dipped roughly 2.4% to $1,015.05 on Wednesday, following a close of $1,039.51 the day before. Intraday, the stock fluctuated between $1,012.09 and $1,038.96.
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming
Pfizer shares were down 1.7% at $26.06 in late morning trade on Wednesday after the U.S. Centers for Medicare & Medicaid Services added its arthritis drug Xeljanz to the next round of Medicare drug price negotiations. CMS said the talks will run in 2026, with negotiated prices slated to take effect on Jan. 1, 2028, and companies facing a Feb. 28 deadline to sign participation agreements.
Why Shuttle Pharmaceuticals stock (SHPH) is moving again before the opening bell
Shares of Shuttle Pharmaceuticals Holdings jumped roughly 12% to $2.27 in premarket action Wednesday, rebounding after an 8.6% drop the day before.
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus
GSK shares fell 1.8% to 1,828.5 pence by mid-morning Wednesday in London, retreating after two days higher. The stock slipped 34 pence from Tuesday’s close, with about 951,000 shares traded, per LSE data.
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom
Shares of Gilead Sciences climbed 2.3% to close at $140.97 on Tuesday, marking a fresh 52-week high and extending their winning streak to five sessions. Trading volume hit roughly 10.5 million shares, surpassing the stock’s 50-day average, according to MarketWatch data.
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next
Shares of Johnson & Johnson ticked up Tuesday following U.S. regulatory clearance to broaden the indication for its Darzalex Faspro treatment in newly diagnosed multiple myeloma, a type of blood cancer. The stock ended the session 1.34% higher at $224.46 and showed little movement after hours.
TechStock² Updates
